Nuwellis, Inc.
Moat Score — Nuwellis, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 1 / 5 | Nuwellis holds FDA clearance for the Aquadex SmartFlow system and some underlying device IP, but the asset base is thin relative to its $316.3 million accumulated deficit, and much of the differentiation rests on clinical data rather than hard-to-replicate technology. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | The company moved manufacturing to a third party, KDI Precision Manufacturing, in 2025, and nothing in the filing suggests Nuwellis produces its console or consumables more cheaply than a well-funded competitor could. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With a going-concern warning and cash runway only through Q2 2026, Nuwellis is in no position to exert pricing power; its priority is adoption and reimbursement support, not margin expansion. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect; one hospital's adoption of Aquadex does not make the product more valuable to another hospital. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Hospitals that adopt the console-plus-consumable Aquadex model face modest recurring-purchase switching costs, but the installed base is small and the company's own international retrenchment shows this stickiness has limits. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The company states there are no direct U.S. competitors in heart failure or critical care other than diuretics, a genuinely uncontested niche, though the addressable market is small enough, and the company undercapitalized enough, that this position is actively being tested by Medtronic/DaVita's well-funded Mozarc Medical venture. |